Monitor for the effectiveness of the S-1 and the commencement of trading. The key catalyst will be the announcement of a definitive business combination target within the 18-month window. The sponsor's affiliation with Allarity Therapeutics (ALLR) may influence the target selection process.
Executive Summary
Allarity Acquisition Corp. is a newly formed blank check SPAC seeking to raise $100M via 10M units at $10/unit to acquire a business, with a focus on life sciences/biotech. The sponsor is a wholly owned subsidiary of Allarity Therapeutics (ALLR). The filing is an amendment to the S-1 registration statement, updating financials and offering details. No target has been identified.
Key Financial Metrics
Key Facts
- Blank check SPAC seeking to raise $100M (10M units at $10/unit) with a 45-day over-allotment option for up to 1.5M additional units.
- Sponsor is ALLR Sponsor LLC, a wholly owned subsidiary of Allarity Therapeutics (ALLR), which purchased 3,833,333 founder shares for $25,000 (~$0.0065/share).
- Sponsor will purchase 2.6M private warrants at $1.00/warrant ($2.6M total) in a concurrent private placement.
- Trust account will hold $100.75M ($10.075/share) from the offering and private placement proceeds.
- Company has 18 months from closing to complete an initial business combination or will liquidate and redeem public shares.
- As of May 31, 2026, the company had no cash, a working capital deficit of ($112,519), and total shareholders' equity of $25,000.
- Management team has experience in life sciences and biotechnology, including through Allarity Therapeutics.
- Founder shares represent 25% of post-offering ordinary shares (excluding representative shares) and have anti-dilution rights.
Financial Impact
Gross proceeds of $100M from the IPO and $2.6M from private warrants, with $100.75M deposited in trust. Net proceeds outside trust of ~$500K for working capital.
Risk Factors
- No operating history and no identified acquisition target.
- 18-month deadline to complete a business combination or face liquidation.
- Significant dilution from founder shares purchased at nominal price ($0.0065 vs $10 offering price).
- Conflicts of interest with sponsor and management team who have incentives to complete a deal.
- Potential inability to raise additional financing or secure shareholder approval for a business combination.
Documents Analyzed
This report is based on 2 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| S-1/A Filing (Primary) | 0001493152-26-045457 |
| Exhibit: ex1-1.htm | 0001493152-26-045457 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 9, 2026 17d ago | S-1/A | — | awaiting T+20 | — | — |
Oct 6, 2026 20d ago | S-1/A | — | awaiting T+20 | — | — |
Oct 2, 2026 24d ago | S-1/A | — | awaiting T+20 | — | — |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers